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Abstract
Introduction Preschoolers have the highest rate
of emergency visits and hospitalisations for asthma
exacerbations of all age groups, with most triggered by
upper respiratory tract infections (URTIs) and occurring
in the fall or winter. Vitamin D insufficiency is highly
prevalent in Canadian preschoolers with recurrent asthma
exacerbations, particularly in winter. It is associated
with more URTIs and, in patients with asthma, more oral
corticosteroid (OCS) use. Although evidence suggests that
vitamin D supplements significantly decrease URTIs and
asthma exacerbations requiring OCS, there is insufficient
data in preschoolers. This study aims to determine the
impact of vitamin D3 supplementation on exacerbations
requiring OCS, in preschoolers with recurrent URTI-induced
asthma exacerbations.
Methods and analysis This is a phase III, randomised,
triple-blind, placebo-controlled, parallel-group multicentre
trial of vitamin D3 supplementation in children aged
1–5 years, with asthma triggered by URTIs and a recent
history of frequent URTIs and OCS use. Children (n=865)
will be recruited in the fall and early winter and followed
for 7 months. They will be randomised to either the (1)
intervention: two oral boluses of 100 000 international
unit (IU) vitamin D3 (3.5 months apart) with 400 IU vitamin
D3 daily; or (2) control: identical placebo boluses with
daily placebo. The primary outcome is the number of
exacerbations requiring OCS per child, documented by
medical and pharmacy records. Secondary outcomes
include number of laboratory-confirmed viral URTIs,
exacerbation duration and severity, parent functional
status, healthcare use, treatment deintensification, cost
and safety.
Ethics and dissemination This study has received
ethical approval from all sites. Results will be disseminated
via international conferences and manuscripts targeting
paediatricians and respirologists, and to families of
asthmatic children via our Quebec parents–partners
outreach programme. If proven effective, findings may
markedly influence the management of URTI-induced
asthma in high-morbidity preschoolers and could be

Strengths and limitations of this study
►► This multicentre randomised controlled trial will be

the largest paediatric study testing the impact of
high-
dose vitamin D supplementation, compared
with placebo, as adjunct to inhaled corticosteroids,
in preschool-aged children with predominantly viral-
induced asthma.
►► This trial uses a pragmatic patient selection and
easily applicable intervention to maximise subsequent implementation in practice.
►► The main outcome, the number of exacerbations
treated with rescue oral corticosteroids, was selected by parents–partners as clinically meaningful,
which can be successfully ascertained by pharmacy
and medical records in all randomised participants:
it is likely to change practice if a 25% reduction is
documented.
►► Because of the variability in diet, vitamin D supplement use, sun exposure and skin colour, it is impossible to control all factors that may affect circulating
25-hydroxyvitamin D levels; however, it is expected
that these factors will be balanced between groups
due to randomisation and recruitment only in fall
and early winter.
►► Despite the ethical requirement of allowing eligibility for children taking up to 400 IU of supplemental
vitamin D, there is a low risk of dilution of effect,
given that the average dietary and supplemental
intake in the target population is 60% lower than
recommended.

directly implemented into practice with an update to
clinical guidelines.
Trial registration number NCT03365687.

Introduction
Preschool-
aged children have the highest
rate of emergency department (ED) visits
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inverse relationship between serum 25OHD and airway
reactivity.27 An immune-modulating and synergistic effect
of vitamin D with ICS on airway inflammation may also
exist, with a paediatric RCT reporting a significant reduction in ICS dose in the vitamin D group compared with
controls,28 confirming observational findings.29–32 While
bone health is optimised with serum 25OHD≥75 nmol/L,
that is, vitamin D sufficiency,33 the thresholds for optimal
immune, anti-inflammation and respiratory function are
unknown, but believed to be higher. Hence, exploration
of the impact of vitamin D on immune and inflammatory
mechanistic pathways34–36 would enhance understanding
of mechanisms of action.
In contrast to healthy children,37 vitamin D insufficiency is highly prevalent year-
round in children with
asthma,29 38–41 peaking in winter.42 In order to prevent the
well-
documented September asthma epidemic43 associated with URTIs, a rapid increase in, and maintenance of,
serum 25OHD over the fall and winter is crucial. A single
oral bolus of 100 000 international unit (IU) vitamin D3
rapidly increases 25OHD levels in preschoolers,40 41 but
levels are not sustained without a repeat bolus and daily
supplementation. In our first pilot RCT, a single bolus
of 100 000 IU was compared with a single placebo bolus,
with both groups receiving daily 400 IU vitamin D3 for
6 months: the intervention significantly raised serum
25OHD with 100% versus 55% of preschool-aged children, respectively, achieving a sustained level ≥75 nmol/L
at 3 months. Despite a modest further increase in
25OHD, attributed to daily supplementation, there was
no significant group difference at 6 months, underlying
the need for a repeat bolus.41 In our second pilot RCT,
comparing two 100 000 IU vitamin D3 versus placebo
boluses, 3.5 months apart, without daily supplementation, a rapid increase in serum 25OHD was observed
10 days postbolus; however, serum 25OHD returned to
baseline levels, with no significant group difference at
3.5 months, underlying the need for daily supplementation.40 This is concordant with prior literature suggesting
no sustained effect of bolus supplementation alone on
serum 25OHD or health outcomes.40 41 44–61 In our pilot
trials, only two participants in the intervention group had
a serum 25OHD>250 nmol/L after the first or second
bolus; however, this was not associated with hypercalciuria or hypercalcaemia and there were no cases of
vitamin D toxicity (serum 25OHD>500 nmol/L).40 41 We
concluded that two bolus doses of 100 000 IU, given 3.5
months apart, with daily supplements of 400 IU vitamin
D3 would ensure a rapid and sustained increase of serum
25OHD. Although routinely used in Europe,62 safety data
remain scarce:45 47 50 contributing additional safety data
on 100 000 IU bolus use appears worthwhile.
The protocol of a placebo-
controlled parallel-
group
triple-blind RCT to explore the impact of vitamin D3 supplementation on reducing exacerbations in preschoolers
with viral-
induced asthma is described herein, as per
Standard Protocol Items: Recommendations for Interventional Trials guidelines (online supplementary file 1).
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and hospitalisations due to wheeze/asthma among all
age groups,1 with annual ED visit rates of 23–42/10002;
on average, one in three are hospitalised following an
ED visit.2 Most exacerbations are triggered by viral upper
respiratory tract infections (URTIs),3 4 which occur
frequently in preschool-aged children. URTIs cause more
severe exacerbations than other triggers,5 and are associated with poorer response to oral corticosteroids (OCS).6
Although daily or pre-emptive high-dose inhaled corticosteroids (ICS) as monotherapy have been identified as
effective management strategies for preschool asthma,7
50% still require rescue OCS within 6 months.8–10 Yet, in
case of treatment failure, there is no official recommendation for step-up therapy as there is only one published
trial in preschool-
aged children testing the benefit of
adjunct therapy to ICS.11 The dearth in knowledge to
manage high-morbidity preschoolers with ongoing exacerbations despite ICS monotherapy underlines the crucial
need for new prevention strategies.12
A 2016 systematic review of randomised controlled trials
(RCT) testing vitamin D supplementation in patients
with asthma found vitamin D reduced the rate of exacerbations requiring OCS by 36% (RR 0.64, 658 adults/22
preschoolers) and acute-
care visits/hospitalisations by
61% (OR 0.39, 664 adults/277 school-aged children/22
preschoolers).13 Due to the under-
representation of
preschoolers and participants with moderate/severe
asthma, considerable heterogeneity in vitamin D dosing
and ICS cointervention, and the paucity of trials, there
was insufficient power to explore subgroup differences;
it thus remains unclear whether patient (eg, age, baseline
serum 25-hydroxyvitamin D (25OHD) level, genetic variation) or treatment (eg, vitamin D schedule, ICS use) characteristics modify the magnitude of benefit. Subsequent
paediatric trials using various populations, interventions
and outcomes led to conflicting results.14 15 Clearly, there
is a need for an adequately powered, confirmatory efficacy trial, to determine if vitamin D3 supplementation,
as adjunct to ICS, reduces exacerbations requiring OCS
in preschoolers with viral-induced asthma, irrespective of
serum baseline 25OHD.16
Exploration of potential mechanisms of action would
further elucidate the role of vitamin D in asthma. A
protective effect of vitamin D on upper (OR 0.64)17 and
lower (OR 0.58)18 respiratory infections, and in school-
aged children with viral-
induced asthma (RR 0.26),19
has been previously reported. However, the absence of
laboratory confirmation of infection in most trials raises
the possibility of outcome misclassification: only one
trial objectively documented infection (influenza A),
reporting a significant reduction (RR 0.58) in exacerbations with vitamin D supplements.20 In most tissues,21–23
infection or allergen exposure induce the expression
of enzyme CYP27B1 that converts 25OHD into active
1,25-
dihydroxyvitamin D; the latter binds to nuclear
vitamin D receptor, which regulates the transcription of
over 1000 genes,24 25 including several associated with
bronchial smooth muscle cells,26 explaining the observed
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Hypothesis
We hypothesise that vitamin D3 supplementation will
reduce the number of exacerbations requiring OCS per
child by 25%, versus placebo, in children aged 1–5 years
with recurrent moderate or severe viral-induced asthma
exacerbations, and who are not at risk for vitamin D deficiency at baseline.

Figure 1 Study design and participant flow through the
7±0.5 month study.

The trial has been designed with consideration of several
key factors, namely (i) pragmatic enrolment of eligible
children irrespective of atopy, phenotype and baseline
serum 25OHD to facilitate implementation; (ii) timing
of intervention in the fall and early winter, with study
period continued throughout winter to coincide with the
peak incidence of exacerbations and URTIs and seasonal
decline in serum 25OHD; (iii) use of a safe, easily implementable intervention, to achieve a rapid and sustained
rise in serum 25OHD, with bolus administration coinciding with usual clinic visits; (iv) ICS prescribed in all
participants according to Canadian recommendations63;
(v) selection of a clinically meaningful, parent-approved
primary efficacy outcome known to influence practice;
(vi) exploration of potential mechanisms of action and
(vii) safety profile documentation. If proven effective, this
approach would markedly influence paediatric asthma
management and could be directly implemented in clinical practice.
Research questions and study hypothesis
Objectives
The primary question is whether two oral doses of
100 000 IU vitamin D3 (administered 3.5 months apart)
plus daily 400 IU vitamin D3 decrease the number of
asthma exacerbations requiring OCS, versus placebo,
in preschool-aged children with recurrent moderate or
severe viral-induced exacerbations, treated with daily or
pre-emptive high-dose ICS.
Additionally, the study will examine if, compared with
placebo, the vitamin D intervention: (i) reduces the mean
number of laboratory-confirmed viral respiratory infections; reduces the (ii) severity, (iii) duration of asthma
symptoms and (iv) the intensity of rescue ß2-agonist use,
during exacerbations; (v) improves parental functional
status during exacerbations; (vi) reduces the mean
Jensen ME, et al. BMJ Open 2019;9:e033075. doi:10.1136/bmjopen-2019-033075

Methods and designs
Study design
This is a multicentre, phase III, randomised, triple-
blind, placebo-controlled, parallel-group trial comparing
supplemental vitamin D3 and placebo, both administered
as adjunct to ICS (figure 1).
This study is conducted over 4 years (first participant
recruited: 1 October 2018; estimated study completion:
December 2022) at seven Canadian hospitals: Sainte-
Justine University Hospital Centre (CHUSJ), McGill
University Health Centre (MUHC), Sherbrooke University Hospital Centre, Quebec University Hospital Centre,
Children’s Hospital of Eastern Ontario, Children’s
Hospital London Health Sciences Centre and British
Columbia Children’s Hospital. Additional sites will be
enlisted, if needed.
Subjects
Children are eligible if they are aged 1–5 years, with a
physicians’ diagnosis of asthma based on clinical signs of
airflow obstruction and reversibility according to Canadian guidelines,63 a recent history of asthma exacerbation(s) requiring OCS (≥1 in the past 6 months or ≥2 in
the past year, documented in pharmacy and/or medical
records), frequent URTIs (≥4 in the past year) and URTIs
identified by parents as the main asthma trigger.
Children are excluded if they meet any of the following
criteria: current intake/intention to use >400 IU/day of
vitamin D supplement, or combined dietary and supplemental vitamin D intake that would exceed the recommended daily upper limit (ie, 2500 IU for children aged
1–3 years and 3000 IU for children aged 4–8 years)65 if
combined with the intervention dose; extreme prematurity (<28 weeks gestation); no vitamin D supplementation if exclusively breastfed in the past 6 months;
vitamin D restrictive diet; undernourished (body mass
index (BMI)-for-age in children≥2 years of age, or either
weight or length for age in those <2 years, less than the
third percentile); recent (<1 year) refugees and immigrants from regions at high risk of rickets; other chronic
3
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number of asthma-related ED visits; (vii) is associated
with de-intensification of ICS therapy and (viii) is cost-
effective. This study will examine the intervention’s safety
profile by assessing whether there is a group difference
in the proportion of children with: clinically significant
(ix) hypercalciuria and (x) hypercalcaemia; (xi) serum
25OHD>250 nmol/L64 and (xii) adverse health events
(AHE). It will also assess various exploratory outcomes.

Open access

Study intervention
Intervention group participants receive a 2 mL oral bolus
of 100 000 IU vitamin D3 (50 000 IU cholecalciferol/mL)
at randomisation in the fall or early winter, followed by a
second 2 mL oral bolus of 100 000 IU vitamin D3 3.5±0.5
months later. Participants also receive a total of five 50 mL
coded bottles, containing a 400 IU vitamin D3/mL preparation, to be administered at a dose of 1 mL/day using
a dropper, for 7±0.5 months. Each bottle contains 50
daily doses. Placebo group participants receive an identical 2 mL placebo bolus, and daily dose of 1 mL placebo
preparation, with administration timing identical to the
intervention group.
Randomisation and masking
Using a computer-
generated random list, stratified by
site, children are allocated in a 1:1 ratio to the intervention or placebo group, using permuted block randomisation method to enhance concealment. Site-specific group
allocation codes are held locally in a secure location
with restricted access by each Site pharmacy, the CHUSJ
Central Pharmacy and the independent biostatistician.
The manufacturer (Euro-
Pharm International Canada
Inc., Montreal, QC Canada) provides the vitamin D3
and placebo preparations, identical in appearance and
taste, in coded latex-free bottles. The allocated treatment
number, obtained at enrolment through a web-
based
randomisation system, Research Electronic Data Capture
(REDCap),66 is forwarded to the Site pharmacy, which
prepares the bolus in a coded syringe and the coded daily
dose bottles, in masked kits. Research personnel administer orally the coded bolus dose to participants and
provide daily dose bottles. Treatment compliance is ascertained by confirmation of bolus retention and pharmacy
weighting of returned bottles. All participants, parents,
research personnel, physicians and analysts involved in
the trial are blinded to group allocation; only pharmacists
are unblinded. At study endpoint, parents, physicians and
research personnel are asked to guess the child’s group
allocation. Efficacy and safety analyses will be performed
under allocation concealment, with unblinding after trial
completion and primary outcome analysis.

(500 mg for children 1–3 years; 800 mg for children 4–8
years) is recommended.65
Study procedures
Screening
Potentially eligible children are approached and screened
for enrolment in asthma, chest or allergy clinics, asthma
education centres, EDs and hospital units at participating
sites from April to January; a successful strategy in previous
trials.8 40 41 Advertisements may be placed in health institutions, newspapers, social media and online, where parents
are invited to complete an online screening form and, if
eligible and interested, to solicit a phone appointment
with the research team to confirm eligibility, explain the
study and schedule the randomisation visit.
Randomisation and follow-up contact visits
Randomisation occurs between 1 September and 31
January, with a 7-
month follow-
up. Participants attend
three research visits (randomisation, 3.5±0.5 months,
and 7±0.5 months) and receive six follow-up phone calls
(7±3 days after each bolus, then monthly). Each contact
serves to screen for AHEs; inquire about recent exacerbations and URTIs, related parental work absenteeism and
expenses, and concomitant medication use; and remind
parents to complete questionnaires and collect a nasal
swab during events (table 1).
Covariates
At baseline, skin colour is assessed using a visual adaptation of the validated Fitzpatrick scale.40 41 67 A blood
sample is also drawn for a subsequent analysis of specific
serum IgE (Phadiatop +Fx5 food allergen mix or equivalent).68A nasal secretion sample is taken at randomisation and 3.5±0.5 months using a paediatric flocked
mid-turbinate swab, placed in a tube containing 1 mL
Universal Transport Medium (Copan Italia, Brescia,
Italy), and stored at −80°C before quantification of the
number and type of viruses using PCR analysis (Research
St. Joseph’s, Hamilton, ON Canada).69 70 At each visit,
height and weight are measured, and dietary and sun
exposure questionnaires, are completed.

Cointerventions
Following Canadian guidelines,63 daily ICS or pre-emptive
high-dose ICS with/without additional therapies, as per
clinical judgement, is required at randomisation. Where
calcium intake is identified as insufficient via dietary
recall, dietary change or calcium supplements sufficient
to meet the daily calcium Estimated Average Requirement

During an event
up or URTI, parents are instructed to
During a flare-
collect a nasal swab and complete: (1) the validated
item Asthma Flare-
up Diary for Young Children
17-
(ADYC)71 daily throughout the event to document symptoms and, at the end of the event, both the (2) validated
21-item Effect of a Child’s Asthma flare-up on Parents (ECAP)
questionnaire72 to measure parental quality of life and
(3) summary-of-event form to capture healthcare utilisation, including hospital/pharmacy name. Parent collection of nasal swabs has been shown to be comparable to
physician collection.73 Nasal swabs are frozen at −20°C
until delivered (courier or in person) to the recruitment
site and stored at −80°C prior to PCR analysis. Reminders
containing instructions with links to complete online
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respiratory disease; diagnosed condition(s) or use of
medication(s) that alter calcium or vitamin D absorption/metabolism and anticipated follow-up difficulties.
Exclusions minimise the risk of including children with
rickets and vitamin D deficiency without screening for
serum 25OHD at baseline.

Study timeline and procedures

 

 

(✓)refers to a specimen sampled but not routinely analysed unless specifically requested by the Site endocrinologist.
*The delay is counted since the second bolus at 3.5±0.5 months.
†In a subset of patients recruited in two institutions.
ALP, alkaline phosphatase; d, days; m, months; URTI, upper respiratory tract infection.

(✓)

(✓)

(✓)
✓
(✓)

Serum 25-hydroxyvitamin D

(✓)

✓

✓

 

Urinary calcium:creatinine ratio

 

✓

✓

✓

Serum calcium, phosphorus and ALP

 

✓

✓

✓

 

 
✓

 

 

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

3.5±0.5 m

 

Laboratory analyses

Nasal swab (parent-collected)

Summary of cold or asthma flare-up form

Effect of a child’s asthma flare-up on parents72

Asthma flare-up diary for young children71

 

✓

Daily vitamin D supplement compliance

During each asthma flare-up or URTI

✓

URTIs, exacerbations, medications, emergency visits or
hospitalisations, parental work absenteeism and expenses

 
✓

 

Adverse health events

 

2m

 

✓

✓

✓

 

 

7±3 d*

(✓)

(✓)

✓

 

✓

 

10±3 d*

 

✓

✓

✓

 

 

5m

✓

✓

✓

 

 

6m

(✓)

(✓)

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

7±0.5 m
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Telephone contacts

(✓)

 

Blood samples†

 
✓

Home visits

10±3 d 1 m

Urine samples

 

✓

URTIs, exacerbations, medications, acute care visits or
hospitalisations

Daily vitamin D supplement compliance

✓

✓

Weighting of daily vitamin D bottles

Adverse health events

✓

Dietary intake (vitamin D, Calcium)

✓

✓

Atopy (serum IgE)

✓

✓

Skin colour (Fitzpatrick scale)

Dispensing and/or exchange of parent questionnaires

✓

Sun exposure questionnaire, anthropometry

Nasal swab

✓
✓

Blood and urine samples

Randomisation 7±3 d

Asthma phenotype and treatment

Clinic visits

Table 1
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Risk management
Clinical and biochemical AHEs are monitored throughout
the study and will be reported for all patients at the end
of the study. A urine sample is systematically collected
and analysed for calcium:creatinine ratio five times, that
is, at each visit and at 10±3 days following each bolus.
A non-fasting venous blood sample is collected at each
visit for all participants and, in a subset of consenting
participants, of the CHUSJ and MUHC, systematically at
10±3 days following the first bolus for peripheral blood
mononuclear cell extraction in the two sites (CHUSJ and
MUHC) able to process these samples. Blood samples are
obtained for four main purposes: (i) individual patient’s
safety assessment (eg, serum calcium (Ca), phosphorus
(Ph), alkaline phosphatase (ALP), parathormone); (ii)
intervention safety (eg, as above and serum 25OHD);
(iii) covariate documentation (eg, serum total and
specific IgE) and (iv) exploratory outcomes (eg, gene
expression).
Any abnormal calcium:creatinine value is interpreted
as ‘clinically significant’ or ‘not clinically significant’ by
the blinded Site endocrinologist. If ‘clinically significant’,
a blood aliquot is obtained to measure serum Ca, Ph, ALP,
or a repeat urine calcium:creatinine is analysed. Further
investigation or action for individual patients (including
interruption, cessation, or, with prior notification of Site
investigator, unblinding of the study drug via pharmacy
or by analysis of serum 25OHD) will be selected by the
Site endocrinologist, if needed to ensure patient safety.
To maintain blinding, serum 25OHD aliquots will be
analysed following study completion, unless specifically
requested by the site endocrinologist or Data Monitoring
Safety Board due to patient safety concerns.
In addition, dietary and supplemental vitamin D intake
is systematically monitored throughout the trial to ensure
that excess intake is not occurring.
Outcomes
Primary outcome
The primary outcome, the number of asthma exacerbations requiring OCS per child (ie, within-patient) during
the 7-month follow-up, is ascertained by parental report
at each contact, and confirmed after the final visit (7±0.5
months) via medical and pharmacy records, with parental
consent obtained at enrolment. The success of this strategy
has been demonstrated in previous trials,8 40 41 irrespective of attrition. OCS use is assumed when a patient was
administered or prescribed ≥1 OCS dose for an asthma or
asthma-like event.

of days with symptoms) of symptoms, and the intensity of
rescue β2-agonist use (cumulative daily number of puffs),
during an exacerbation. The ECAP questionnaire72 will
capture parental functional status during an exacerbation. The mean number of ED visits for asthma is captured
via the parent-
completed summary-
of-
event form and
confirmed by medical records. Any step-up or step-down
in ICS therapy is captured via physician questionnaire at
each visit. The intervention cost will be determined by
documenting: (i) family expenses during an exacerbation
(ie, medications, ED visits, hospitalisations, work absenteeism and out-of-pocket expenses), captured via parent
report at each contact; (ii) healthcare cost (ie, ED visits,
hospitalisations, medications and physician visits) and
(iii) intervention cost, determined through drug manufacturer, nursing time and facility resources.
Safety outcomes
The primary safety outcome, a ‘clinically significant’
hypercalciuria event, is based on the site endocrinologist’s clinical interpretation of urinary calcium:creatinine
results exceeding pre-established laboratory standards.74
Similarly, a ‘clinically significant’ hypercalcaemia event
is based on the site endocrinologist’s clinical interpretation of serum calcium results exceeding pre-established
laboratory standards. Elevated serum 25OHD is defined
as a value >250 nmol/L,64 measured at the CHUSJ Central
Laboratory after study completion to maintain blinding.
Serious and non-serious AHEs will be recorded at each
contact in accordance with guidelines adopted by Health
Canada.75
Exploratory outcomes
Several outcomes pertaining to immune, infection,
inflammation, bone and genetic markers (including
changes in gene expression) and lung function will be
documented.
Data management and monitoring
The Applied Clinical Research Unit at CHUSJ will oversee
randomisation, data management, progress monitoring
and all analyses, including those for the Data Safety Monitoring Board (DSMB). REDCap66 will be used for online
data entry and management. A combination of remote
monitoring activities and routine monitoring visits are
conducted to ensure that each Site adheres to the study
protocol, Good Clinical Practice guidelines and data
collection completeness.

Secondary outcomes
The mean number of URTIs will be quantified via PCR
analysis of nasal swabs, collected by parents during an
exacerbation. The ADYC71 is used to ascertain the severity
(sum of the daily score) and duration (cumulative number

Sample size calculation
Based on our previous data,8 the number of OCS per
child is well approximated by a Poisson distribution. The
mean number of events per interval (λ) was conservatively
estimated at 0.55 OCS/child in our placebo arm (based
on prorated event rates in preschoolers receiving daily/
pre-emptive ICS in previous trials).8–10 A sample size of
400 children per arm will provide 80% power with a two-
tailed alpha of 5% to detect a 25% relative reduction in
the mean number of events (ie, λ=0.55 in the placebo, vs
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questionnaires are sent by SMS or email at randomisation
then regularly throughout the study period.
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Statistical analysis
Primary outcome
An intention-to-treat analysis will be carried out with all
randomised children by treatment group. The primary
outcome will be analysed using a Poisson regression
model (including parameters for site stratification) to
compute the rate ratio (incidence) for comparing the
mean (within-patient) number of OCS per child during
the 7-month follow-up, with over-dispersion and offset
variable for variations in person-time. A formal interim
analysis will be performed when approximately 50% have
been enrolled and completed follow-up. The DSMB will
review the interim safety and efficacy data. Interim and
final analyses will be adjusted to maintain an overall type
I error rate, based on Lan and DeMet’s implementation
of the O’Brien-
Fleming grouped sequential stopping
boundary. This implementation will permit early stopping
only for strong positive or negative effects and maintains
nearly all the nominal power for the final analysis. Seven
subgroup analyses are planned on baseline: serum 25OHD
(<75 vs ≥75 nmol/L), ICS therapy (pre-emptive vs daily),
asthma phenotype (viral-
induced vs multitrigger), sex
(male/female), atopy (specific multiallergen IgE ≤0.35
or >0.35 kUa/L),68 BMI (Z-score ≤2 vs >2 SD)76 and skin
colour (five categories).67
Secondary and safety outcomes
The mean number of laboratory-confirmed viral URTIs
will be compared between groups using a negative binomial model that includes a shape parameter and site stratification. Symptom severity during an exacerbation will
be compared between groups using a generalised linear
regression model, adjusting for event clustering in individuals with an offset variable for variations in person-time, if
relevant. Similar analyses will be carried out for symptom
duration, intensity of rescue β2-agonist use, and parental
functional status, during an exacerbation. The Mantel-
Haenszel method, stratified by site, will serve to compare
categorical outcomes, including the number of children
with ≥1 episode of clinically significant hypercalciuria,
hypercalcaemia, elevated serum 25OHD, and AHEs; and
Poisson regression to compare the mean number of ED
visits. No adjustment for multiple outcomes is planned.
The cost-effectiveness of the intervention will be evaluated using standard trial-
based economic evaluation
methods, employing a nested loop of imputation of
missing values (due to attrition), regression (to adjust for
baseline variables) and bootstrapping (to estimate uncertainty).77 The main outcome of the economic evaluation
will be the incremental costs per exacerbation avoided.
The main analysis will adopt a public health payer
perspective, where direct medical costs will be considered.
A secondary analysis, adopting a societal perspective,
Jensen ME, et al. BMJ Open 2019;9:e033075. doi:10.1136/bmjopen-2019-033075

will evaluate loss of school time and parental/caregiver
productivity loss.
Patient and public involvement
Our patient-
engagement initiative ensured parents–
partners involvement in the study design and conduct.
Consultation with parents of preschoolers with asthma
contributed to our primary outcome selection, to
approving our intervention and secondary outcomes
(eg, disease burden), to enhancing procedures to optimise feasibility and implementation (using electronic
reminders and online vs paper completion of questionnaires) and to maximise recruitment, protocol adherence
and retention. Parents–partners involved in this trial, and
those involved in the Canadian Respiratory Research
Network patient platform, will contribute to the dissemination plan to ensure that results are communicated to
as many families of preschoolers with asthma as possible.
Ethics and safety considerations
This study has been independently approved by the
CHUSJ Research Ethics Board (REB), serving as the
multicentre REB in Quebec; the Children’s Hospital of
Eastern Ontario REB, serving as the multicentre REB in
Ontario and the local REB of all participating institutions
(online supplementary file 2), all of which abide by the
principles of the Helsinki Declaration. A non-objection
letter from Health Canada has been obtained to use high-
dose vitamin D and placebo in the context of this study
(#228409). Written informed consent for study participation and biobanking specimens for ancillary studies is
obtained from parents of all participants, with the knowledge that participation is voluntary and can be withdrawn at any time with no effect on their current/future
medical care (online supplementary file 3). Care will
be provided to those who suffer harm from trial participation. All protocol amendments will be submitted to
Health Canada, investigators and REBs; if these changes
imply a revision of consent forms, ongoing trial participants will be informed of new modifications to provide
informed consent.
All information obtained during the study will be kept
confidential according to law. Data will be collected
directly into electronic Case Report Forms or transcribed from paper versions, as approved by Health
Canada. Data safety and confidentiality will be upheld
at all data collection stages via assignment of a unique
research code to each participant, with data and
samples kept under lock and key, electronic password
protection and access restricted to study personnel. For
medical safety reasons, a copy of the consent form will
be included in the participant’s medical record, where
allowable by the site institution. The principal investigator at each site will be responsible for secure data
storage for 25 years and for biobanked specimens as
long as adequate management and safeguards can be
ensured. The Central site, CHUSJ, will store only coded
data. Samples collected during the study will be labelled
7
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λ=0.4125 in the intervention, group). This is a conservative estimate, given the observed rate ratio of 0.64 (95%CI
0.46 to 0.90) in a 2016 meta-analysis.13 Allowing for 10%
attrition, we aim to recruit 865 children (432/arm).
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Implementation and dissemination
This trial employs pragmatic patient selection without
serum 25OHD prescreening and intervention to maximise subsequent implementation into practice. If effective
in reducing short-term morbidity, this approach would
be readily implementable and could markedly influence
asthma management in high-morbidity preschoolers.
No participant identifiers will be used in the dissemination of this research. Results will be disseminated
to the medical community via national/international
conferences and publications in peer-reviewed journals,
and to families of preschoolers with asthma by involving
parents–partners in the disseminating plan.
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There are two, though extremely low, theoretical risks
with vitamin D supplementation in Canadian children:
hypocalcaemia, secondary to a rapid increase in bone
remodelling at baseline in the condition where the
participant presents with an undiagnosed active rickets;
and hypercalcaemia/calciuria, due to enhancing effects
of vitamin D on intestinal absorption of calcium. Our
trial design has incorporated strategies to mitigate risk.
We are excluding at enrolment patients at high risk
of vitamin D deficiency and are routinely evaluating
calcium and vitamin D dietary intake, both to exclude
the rare child with rickets (Canadian annual incidence
1.6–2.9/100 000 children),78 79 in whom vitamin D,
without calcium, supplementation could lead to hypocalcaemia. In the first hypothetical case of rickets, ALP
levels should also be elevated and be a second flag to
exclude this child from the study. Any toxicity in vitamin
D is mediated via elevated serum calcium (with normal
or elevated serum phosphorous and normal or low ALP);
if serum calcium is normal, there is no clinical risk of
vitamin D toxicity to the individual. To minimise the
risk of hypercalcaemia (which could signal vitamin D
intoxication), we have selected a bolus dose routinely
recommended in France,62 with no documented adverse
effects,45 47 50 are excluding children with recent excessive
vitamin D supplementation, are systematically screening
urine calcium:creatinine (the most sensitive marker of
elevated serum calcium) and serum biomarkers (ALP,
calcium and phosphorous) at randomisation, with
urine screening periodically throughout the trial, and
implemented a process whereby all abnormal values are
reviewed by the Site endocrinologist for clinical interpretation and management where indicated. Finally, as
we expect a fair proportion of enrolled children to have
vitamin D insufficiency (ie, 25–75 nmol/L) at study entry,
all participants will be advised at the end of the study if
their usual (dietary and supplemental) vitamin D intake
was below recommendations, and provided general
dietary advice to meet the Canadian recommended daily
intake.33
Serious adverse drug reactions will be reported to
the Therapeutic Products Directorate (Health Canada)
where they are ‘unexpected’ and the investigator deems
there is a reasonable suspected causal relationship to the
treatment, or, they are ‘expected’ and there is an increase
in the incidence or the severity is of clinical importance.75
An independent DSMB, comprised of relevant experts
(paediatric respiratory medicine, paediatric endocrinology, biostatistics and vitamin D) has been established,
with terms of reference; it periodically reviews the occurrence of any ‘clinically significant’ abnormal hypercalciuria/calcaemia results and the number and distribution
of AHEs, with notification of serious unexpected AHEs
provided within 48 hours of their reporting.
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